Veronika Reidel und Catharina - Info zur Person

Prof. (SHB) Dr. med. Dirk Hempel - Facharztzentrum ...

www.facharztzentrum-ffb.com

Selective inhibition of BCL-2 is a promising target in patients with high-risk Myelodysplastic Syndrome and adverse mutational profile. Veronika Reidel 1, Johanna Kauschinger 1, Richard Tilmann Hauch 1, Catharina Müller-Thomas 1, Niroshan Nadarajah 2, Rainer Burgkart 3, Burkhard Schmidt 4, Dirk Hempel 5, Anne Jacob 1, Julia Slotta-Huspenina 6, Ulrike Höckendorf 1, Christian Peschel 1,7 ...

Protein levels of BCL-2, BCL-XL and MCL-1 predict resistance to pro ...ur.booksc.me › book

ur.booksc.me

... Veronika Reidel, Catharina Müller-Thomas, Höckendorf Ulrike, Christian Peschal, A. Oostendorp Robert, Katharina S. Götze, Phillip J. Jost Technische ...

Clinical Lymphoma Myeloma and Leukemia | Proceedings of the Society...

www.sciencedirect.com

Stefanie Jilg, Veronika Reidel, Catharina Müller-Thomas, Höckendorf Ulrike, ... Phillip J. Jost. Pages S42-S43: Download PDF.

May Apoptosis and cell deathcelldeath.wordpress.com ›

celldeath.wordpress.com

· Veronika Reidel, Johanna Kauschinger, Richard T. Hauch, Catharina Müller-Thomas, Niroshan Nadarajah, Rainer Burgkart, Burkhard Schmidt, ...

Veröffentlichungen von Prof. (SHB) Dr. med. …

www.cancer-center.eu

Selective inhibition of BCL-2 is a promising target in patients with high-risk Myelodysplastic Syndrome and adverse mutational profile. Veronika Reidel 1, Johanna Kauschinger 1, Richard Tilmann Hauch 1, Catharina Müller-Thomas 1, Niroshan Nadarajah 2, Rainer Burgkart 3, Burkhard Schmidt 4, Dirk Hempel 5, Anne Jacob 1, Julia Slotta-Huspenina 6, Ulrike Höckendorf 1, Christian Peschel 1,7 ...

Protein levels of BCL-2, BCL-XL and MCL-1 predict resistance to...

www.infona.pl

Stefanie Jilg, Veronika Reidel, Catharina Müller-Thomas, Höckendorf Ulrike, Christian Peschal, A. Oostendorp Robert, Katharina S. Götze, ...

Selective inhibition of BCL-2 is a promising target in patients with...

pubmed.ncbi.nlm.nih.gov

Oncotarget Apr 3;9(25): doi: oncotarget Authors. Veronika Reidel , Johanna Kauschinger , Richard T Hauch , Catharina ...

Article - Combination of 5-Azacytidine and ABT-199 Has a Scilitwww.scilit.net › article

www.scilit.net

· Stefanie Jilg, Mdcal Student Johanna Kauschinger, Mdcal Student Veronika Reidel, Catharina Müller-Thomas, Mdcal Student Richard Hauch, ...

Selective inhibition of BCL-2 is a promising target in Oncotargetwww.oncotarget.com › article › text

www.oncotarget.com

· https://doi.org oncotarget Veronika Reidel, Johanna Kauschinger, Richard T. Hauch, Catharina Müller-Thomas, ...

Veronika Reidel und Catharina Person-Info